ArticleJournal of translational medicine2013
Response of circulating heat shock protein 70 and anti-heat shock protein 70 antibodies to catheter ablation of atrial fibrillation.
Article in Journal of translational medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 31 citations in OpenAlex.
- Heat shock proteins in atrial fibrillation: from bench to bedside.Frontiers in physiology · 2025Review
- Mitochondrial Impairment: A Link for Inflammatory Responses Activation in the Cardiorenal Syndrome Type 4.International journal of molecular sciences · 2023Review
- The Role of Major Biomarkers of Stress in Atrial Fibrillation: A Literature Review.The Journal of innovations in cardiac rhythm management · 2023Review
- Autoantibodies in Atrial Fibrillation-State of the Art.International journal of molecular sciences · 2023Review
- Review
- Alarmins as a Possible Target of Future Therapies for Atrial Fibrillation.International journal of molecular sciences · 2022Review
- Radiofrequency ablation reduces expression of SELF by upregulating the expression of microRNA-26a/b in the treatment of atrial fibrillation.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2022Article
- Review
- The Role of Autoantibodies in Arrhythmogenesis.Current cardiology reports · 2020Review
- Article
- Immunopathogenesis and biomarkers of recurrent atrial fibrillation following ablation therapy in patients with preexisting atrial fibrillation.Expert review of cardiovascular therapy · 2019Review
- [Biomarkers and atrial fibrillation : Prediction of recurrences and thromboembolic events after rhythm control management].Herzschrittmachertherapie & Elektrophysiologie · 2018Review
- Extracellular cell stress (heat shock) proteins-immune responses and disease: an overview.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2018Review
- The detection and role of heat shock protein 70 in various nondisease conditions and disease conditions: a literature review.Cell stress & chaperones · 2015Review
- Inflammation and the pathogenesis of atrial fibrillation.Nature reviews. Cardiology · 2015Review
- Galectin-3 in patients with atrial fibrillation undergoing radiofrequency catheter ablation.PloS one · 2015Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis pilot study investigated the association between heat shock protein 70 (HSP70) and anti-HSP70 antibodies as well as their changes and rhythm outcome after atrial fibrillation (AF) catheter ablation.
methodsWe studied 67 patients with AF (59±11 years, 66% male, 66% lone AF) undergoing catheter ablation. Circulating HSP70 and anti-HSP70 antibody levels were quantified using commercially available assays before and 6 months after catheter ablation. Serial 7-day Holter ECGs were used to detect AF recurrences.
resultsAt baseline, HSP70 was detectable in 14 patients (21%), but there was no correlation between clinical or echocardiographic variables and the presence or the level of HSP70. In contrast, patients with paroxysmal AF (n=39) showed lower anti-HSP70 antibodies (median [IQR] of 43 [28 - 62] μg/ml) than patients with persistent AF (n=28; 53 [41 - 85] μg/ml, p=0.035). Using multivariable regression analysis, AF type was the only variable associated with anti-HSP70 antibodies (Beta=0.342, p=0.008). At 6 months, HSP70 was present in 27 patients (41%, p<0.001 vs. baseline). Similarly, there was an increase of anti-HSP70 antibodies (48 [36 - 72] vs. 57 [43 - 87] μg/ml, p<0.001). AF recurrence rates were higher in patients with HSP70 increase ≥0.025 ng/ml (32 vs. 11%, p=0.038) or anti-HSP70 increase ≥2.5 μg/ml (26 vs. 4%, p=0.033).
conclusionsHSP70 and anti-HSP70 antibodies may - at least in part - be associated in the progression of AF and AF recurrence after catheter ablation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.